Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Treatment

The Family Cognitive Adaptation Training Manual: A Test of Effectiveness

Psychosis

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcome: Primary: Multnomah Community Ability Scale (MCAS) — 67.78; 74.63; 70.00; 74.38 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Family Cognitive Adaptation Training (Behavioral)
Age
Pediatric, Adult, Older Adult · 16+ yrs
Sex
All
Sponsor
Centre for Addiction and Mental Health
Primary completion
Oct 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Multnomah Community Ability Scale (MCAS)
67.78; 74.63; 70.00; 74.38; 21.67; 22.13
SECONDARY
Brief Adherence Rating Scale (BARS)
77.22; 87.50; 59.33; 88.75
SECONDARY
Satisfaction With Life Scale
2.06; 2.18; 1.63; 2.17; 2.00; 2.29
SECONDARY
Involvement Evaluation Questionnaire (IES)
57.72; 49.25; 15.50; 14.13; 8.22; 7.50

Summary

The purpose of this study is to examine the effectiveness of family cognitive adaptation training, including its impact on functioning and caregiver burden. Families that receive the manual will be compared with a control group of families that will not receive the manual. The larger goal is to add to the tools family members have access to better support their family members with schizophrenia.

Eligibility Criteria

Inclusion Criteria

  • the key family member/support is actively involved in the support of the individual with schizophrenia and regularly visits them (i.e., once a week or more frequently) in their home environment
  • the individual being supported is identified (self-identified and identified by the family member) as having a primary diagnosis of schizophrenia
  • the individual with schizophrenia is not in crisis or experiencing other forms of instability (e.g., imminent loss of housing) per verbal report that would threaten the implementation of the manual strategies
  • proficiency in English

Exclusion criteria

  • none
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01768000). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search